



**FemmePharma**  
GLOBAL HEALTHCARE, INC.

## **FemmePharma Receives U.S. Ind Approval for its New Therapeutic Option for Female Urinary Incontinence**

September 15, WAYNE, PA - FemmePharma, Inc., a late stage pharmaceutical company solely focused on developing drugs for the diseases and disorders disproportionately affecting women, announced today the FDA has permitted the Company to open an IND (Investigational New Drug) application for FP1097, a new therapeutic treatment option for female urinary incontinence. The Company will open a Phase IIa human clinical trial. This is FemmePharma's second product to enter human clinical trials. Its first product, an drug for endometriosis, will enter Phase III.

"FemmePharma is pleased to have reached this significant milestone. We look forward to moving FP1097 through the clinical development process," stressed FemmePharma President Gerianne Tringali-DiPiano. "This is an important step toward providing women who suffer from urinary incontinence an effective therapeutic option with fewer of the systemic side effects seen from the products currently available in the market."

### **About Female Urinary Incontinence and FP1097**

Urinary incontinence is defined as the unwanted loss or leakage of urine at an unacceptable place and time. Of the 13 million Americans suffering from this disorder, 80 percent are women. Many sufferers incorrectly believe urinary incontinence is an inevitable part of aging. In fact, 25 percent of women between the ages of 30 and 59 has experienced urinary leakage, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Many suffer with Urinary Incontinence in silence, too embarrassed to confide in friends or healthcare professionals. They feel isolated and withdraw from family, friends and social contact. Daily routines focus around immediate access to bathrooms.

A variety of treatment and management options are available in today's market. Adult diapers and sanitary napkins, while protecting against the "accident," are not treating the disorder. Behavioral techniques such as bladder training and Kegel exercises are often viewed as first-line therapies and can be effective in the mild to moderate cases of the disorder. Surgery and medical insert devices can be expensive, may require hospitalization, and are generally seen as options for the most severe cases.

FemmePharma's research has shown that women prefer to explore non-surgical treatment options when given the choice. Today, the market contains effective pharmacologic treatment options for urinary incontinence. However, women are finding that while these medications are effective in treating the incontinence, the drugs can carry significant systemic side effects, such as dry mouth, sensitivity to bright light, blurred vision, dry eyes, nausea, drowsiness and cardiac manifestations.

Delivered locally, FemmePharma's new drug, FP1097, will have high bioavailability within

- 37 West Avenue • Second Floor
- Wayne, Pennsylvania 19087
- Tel: 610.995.0801
- Fax: 610.995.0825

the pelvic region and affect the local bladder receptors. Regional administration should result in lower systemic side effects. This treatment option should be a viable alternative to women who cannot tolerate currently available pharmacologic treatment options.

**About FemmePharma, Inc.**

FemmePharma was founded by Gerianne Tringali-DiPiano in 1996 to target identifiable unmet needs within the estimated \$35 billion women's healthcare pharmaceutical market. The company is preparing for its Phase III trial for its first drug, a new treatment for endometriosis. It is devoted to developing safe and effective drugs that minimize or eliminate unpleasant side effects associated with many medications by designing them in a manner that is specifically suited to a woman's physiology, with an eye toward the changing needs of women throughout their lives. FemmePharma's mission is to create value by developing innovative "woman-friendly" products in identified areas of highly-unmet needs, low market penetration by existing therapeutic options and high commercial and clinical value. The company has a number of drugs in development based on its proprietary technologies, including new therapeutic options for fibrocystic breast disease and the prevention of HIV/STD transmission. For more information about FemmePharma, please visit its website at [www.fpghc.com](http://www.fpghc.com).

###